Abstract
We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
Keywords: Fragile X, FMRP, RNA binding protein, posttranslational modification, trinucleotide repeat disorder, translation regulation, Fragile X Syndrome, FXS, CGG, FMR1 coding sequence.
Current Protein & Peptide Science
Title:Fragile X Mental Retardation Protein: Past, Present and Future
Volume: 13 Issue: 4
Author(s): Miri Kim and Stephanie Ceman
Affiliation:
Keywords: Fragile X, FMRP, RNA binding protein, posttranslational modification, trinucleotide repeat disorder, translation regulation, Fragile X Syndrome, FXS, CGG, FMR1 coding sequence.
Abstract: We begin by reviewing the first characterization of fragile X syndrome, which ultimately led to cloning of the FMR1 gene. Discovery of the molecular basis of this disorder, including expansion of a trinucleotide repeat, gave insight not only into fragile X syndrome but also into the premutation syndromes. Features of fragile X syndrome are discussed including the patient phenotype down to the neuronal phenotype. The domain features of the fragile X mental retardation protein FMRP are described, as are the mRNAs bound by FMRP and the role of post-translational modifications as regulators of FMRP function. The relatively new role of FMRP in progenitor cells is reviewed, as is FMRP localization in cells and how FMRP is regulated by glutamatergic signaling in the brain. Understanding how metabotropic glutamate receptors impact FMRP has led to novel therapeutic approaches in treating this disorder.
Export Options
About this article
Cite this article as:
Kim Miri and Ceman Stephanie, Fragile X Mental Retardation Protein: Past, Present and Future, Current Protein & Peptide Science 2012; 13 (4) . https://dx.doi.org/10.2174/138920312801619420
| DOI https://dx.doi.org/10.2174/138920312801619420 |
Print ISSN 1389-2037 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Innovative Approaches to Drug Discovery in Bone and Cartilage Diseases.
Bone and cartilage diseases affect the musculoskeletal system and can lead to significant pain, disability and reduced quality of life. Innovative approaches to drug discovery and development are needed to address the unmet medical needs in this area. One promising approach is the integration of Mass Spectrometry (MS), Surface Plasmon ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Peptide and Peptidomimetics: Structure, Assembly, and Applications
Peptides are fundamental biomolecules, imparting structural support, biochemical regulation, and potent pharmacological activity. The therapeutic significance of peptides and peptidomimetics was first demonstrated by the discovery of Insulin, leading to the development of clinically important agents such as Captopril, Semaglutide, and Goserelin, and the antibiotic Lariocidin. Progress in peptide chemistry ...read more
Related Journals
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders
Current Neuropharmacology Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders
Current Drug Targets The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Prospect of a Dopamine Contribution in the Next Generation of Antidepressant Drugs: The Triple Reuptake Inhibitors
Current Drug Targets The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Current Pharmaceutical Design Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders
Current Protein & Peptide Science Serotonin 5-HT<sub>4</sub> Receptors: A New Strategy for Developing Fast Acting Antidepressants?
Current Pharmaceutical Design gp78: a Multifaceted Ubiquitin Ligase that Integrates a Unique Protein Degradation Pathway from the Endoplasmic Reticulum
Current Protein & Peptide Science Neural Stem Cells and Human Induced Pluripotent Stem Cells to Model Rare CNS Diseases
CNS & Neurological Disorders - Drug Targets Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets Humanin: A Possible Linkage Between Alzheimer’s Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Partnerships Between Philanthropy, Government and Investors are Needed to Advance Drug Discovery for Neurodegenerative Diseases
Current Alzheimer Research NMR Structural Studies of Human Cellular Prion Proteins
Current Topics in Medicinal Chemistry Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy
Current Alzheimer Research Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease
Current Alzheimer Research Chlorogenic Acid: A Dietary Phenolic Acid with Promising Pharmacotherapeutic Potential
Current Medicinal Chemistry The Quest to Repair the Damaged Spinal Cord
Recent Patents on CNS Drug Discovery (Discontinued)





